Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Pharvaris N.V.

NASDAQ

Market Cap.

823.26M

Avg. Volume

108.6K

AI Analyst

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Pharvaris N.V.!

Still processing it, give me a bit more time...

Pharvaris N.V. News

Pharvaris N.V. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

HealthcareBiotechnology
pharvaris.com

About Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris N.V. Earnings & Revenue

Pharvaris N.V. Financials

Table Compare

Compare PHVS metrics with:

   

Earnings & Growth

PHVS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

PHVS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

PHVS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

PHVS

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Pharvaris N.V. Income

Pharvaris N.V. Balance Sheet

Pharvaris N.V. Cash Flow

Pharvaris N.V. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquitySell
Return on AssetsSell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Pharvaris N.V. Executives

NameRole
Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, Chief Executive Officer & Executive Director
Ms. Anna Nijdam M.Sc., R.A.Head of Strategic Finance & Principal Accounting Officer
NameRoleGenderDate of BirthPay
Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, Chief Executive Officer & Executive DirectorMale1959567.64K
Ms. Anna Nijdam M.Sc., R.A.Head of Strategic Finance & Principal Accounting OfficerFemale1981

--

Discover More

Pharvaris N.V.

NASDAQ

Market Cap.

823.26M

Avg. Volume

108.6K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Pharvaris N.V. News

Pharvaris N.V. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Pharvaris N.V. Earnings & Revenue

Pharvaris N.V. Income

Pharvaris N.V. Balance Sheet

Pharvaris N.V. Cash Flow

Pharvaris N.V. Financials Over Time

Pharvaris N.V. Executives

NameRole
Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, Chief Executive Officer & Executive Director
Ms. Anna Nijdam M.Sc., R.A.Head of Strategic Finance & Principal Accounting Officer
NameRoleGenderDate of BirthPay
Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, Chief Executive Officer & Executive DirectorMale1959567.64K
Ms. Anna Nijdam M.Sc., R.A.Head of Strategic Finance & Principal Accounting OfficerFemale1981

--

Pharvaris N.V. Insider Trades

No data available

DateNameRoleTransactionTypeShares

No data available

HealthcareBiotechnology
pharvaris.com

About Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

AI Analyst

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Pharvaris N.V.!

Still processing it, give me a bit more time...

Pharvaris N.V. Financials

Table Compare

Compare PHVS metrics with:

   

Earnings & Growth

PHVS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

PHVS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

PHVS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

PHVS

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Pharvaris N.V. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquitySell
Return on AssetsSell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More